Fundraising Fox5AM Ventures — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investorsOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersBay City CapitalJanus Henderson Investors+2 more
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)inJoseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatAndrew Schwab· per SEC Form D
Co-investorsArboretum VenturesF-Prime CapitalTelegraph Hill PartnersHealthQuest CapitalSofinnova Ventures
Bioz provides AI-powered widgets for suppliers that display scientific publication data to build trust and improve sales conversion.
AI & Machine LearningEnterprise SoftwareSaaSLos Altos, US
Daniel Levitt(Executive Officer, Director)Karin Lachmi(Executive Officer, Director)Karin L.(Founder)in
Co-investorsEndurance28Harmonix FundPerot JainStartXTaihill Venture
TMRW Life Sciences builds an FDA-cleared automated platform for managing and storing frozen eggs and embryos, using RFID tracking and an "ivfOS" digital database to monitor and secure specimens.
Digital HealthFemTechHealthtechMedical DevicesNew York, US
Joshua Abram(Director)inTara Comonte(Director)inAlan Murray(Director)in
BoardAndrew Schwab(Director)Vinay Shah(Director)Emily Drabant Conley(Director)in
Co-investorsGV (Google Ventures)TRANSFORMATION CAPITALWhat If Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.